Melanie J. Griffin

St Michael's Hospital, Southwell St
Bristol, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

TRANSFER: ThReatened preterm birth, assessment of the need for in-utero tranSFER between 22 + 0-23 + 6 weeks' gestation, a multicentre prospective service evaluation across the United Kingdom.

TRANSFER: ThReatened preterm birth, assessment of the need for in-utero tranSFER between 22 + 0-23 + 6 weeks' gestation, a multicentre prospective service evaluation across the United Kingdom.

Journal: European journal of obstetrics, gynecology, and reproductive biology

Published: January 22, 2025

Adverse obstetric outcomes in female survivors of adolescentand young adult cancers - Authors' reply.

Adverse obstetric outcomes in female survivors of adolescentand young adult cancers - Authors' reply.

Journal: The Lancet. Oncology

Published: September 09, 2024

Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study.

Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study.

Journal: The Lancet. Oncology

Published: March 05, 2024

Preconception and antenatal care for women with a history of haematopoietic stem cell transplantation: Results of a UK clinician survey.

Preconception and antenatal care for women with a history of haematopoietic stem cell transplantation: Results of a UK clinician survey.

Journal: Obstetric medicine

Published: December 22, 2023

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML.

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML.

Journal: Leukemia

Published: September 30, 2020

The ability of late pregnancy maternal tests to predict adverse pregnancy outcomes associated with placental dysfunction (specifically fetal growth restriction and pre-eclampsia): a protocol for a systematic review and meta-analysis of prognostic accuracy studies.

The ability of late pregnancy maternal tests to predict adverse pregnancy outcomes associated with placental dysfunction (specifically fetal growth restriction and pre-eclampsia): a protocol for a systematic review and meta-analysis of prognostic accuracy studies.

Journal: Systematic reviews

Published: December 11, 2018

A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia.

A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia.

Journal: British journal of clinical pharmacology

Published: October 26, 2016

Diagnostic Biomarkers in Women With Suspected Preeclampsia in a Prospective Multicenter Study.

Diagnostic Biomarkers in Women With Suspected Preeclampsia in a Prospective Multicenter Study.

Journal: Obstetrics and gynecology

Published: July 12, 2016

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 30, 2016

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 24, 2016

Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction.

Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction.

Journal: Placenta

Published: January 27, 2016

A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.

A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 06, 2014

Showing 1-12 of 16

Last Updated: 09/26/2026